Robert Langreth
Verified
As seen in:
Bloomberg News,
UOL Economia,
Forbes,
MSN,
MSN Ireland,
MSN Philippines,
UOL,
Bloomberg Businessweek,
Bloomberg Green Daily,
Bloomberg Markets Magazine,
Cinco Días
and
Science and health reporter at large, Bloomberg News
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Robert Langreth
個別化がんワクチン、多様な種類の腫瘍に効果発揮へ－モデルナCEO
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world
Moderna CEO Confident Cancer Vaccines Will Work Beyond Melanoma
Bloomberg (Bloomberg) -- Moderna Inc.
Moderna y Merck enfrentan dudas de inversionistas pese a los avances de su vacuna contra el melanoma
Bloomberg — Los datos filtrados del tan esperado ensayo clínico de la vacuna contra el melanoma de Moderna Inc. (MRNA) y Merck & Co. (MRK) han generado una inusual discrepancia entre los médicos, que celebraron sus resultados, y Wall Street, donde se produjo una venta masiva de acciones.
Oncologists cheer melanoma data that tanked Moderna's shares
Leaked data from Moderna Inc. and Merck & Co.'s highly anticipated melanoma vaccine trial has led to a rare disconnect between doctors, who celebrated the result, and Wall Street, which sold off the stocks. Normally results of such pivotal drug studies are binary, with doctors, patients and investors all learning whether a novel medicine will make a meaningful difference in people's lives and forming the same conclusion.
Oncologists Cheer Melanoma Data That Tanked Moderna’s Shares (1) Original
Leaked data from and ’s highly anticipated melanoma vaccine trial has led to a rare disconnect between doctors, who celebrated the result, and Wall Street, which sold off the stocks. Normally results of such pivotal drug studies are binary, with doctors, patients and investors all learning whether a novel medicine will make a meaningful difference in people’s lives and forming the same conclusion.
Oncologists Cheer Melanoma Data That Tanked Moderna’s Shares
Photographer: Adam Glanzman/Bloomberg (Bloomberg) -- Leaked data from Moderna Inc.
Oncologists Cheer Melanoma Data That Tanked Moderna’s Shares
5 hours ago For four decades, China’s rise was built on an extraordinary bargain with the world. China offered labor, scale and, eventually, an industrial ecosystem of unparalleled depth. The world supplied technology, capital and markets. China became richer. The rest of the world got cheaper and increasingly …
Tempus shares take a hit after Moderna-Merck melanoma data leak
Introducing 40 young leaders already putting their imprint on the businesses, institutions and communities shaping our future.
データ流出でモデルナ株26%安､メルクと開発のがんワクチン情報が拡散
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world
Moderna cae un récord de 26% tras filtrarse datos de su vacuna contra el melanoma con Merck
Bloomberg — Las acciones de Moderna Inc. (MRNA) y Merck & Co. (MRK) cayeron tras conocerse noticias sobre la tan esperada vacuna personalizada contra el melanoma de ambas empresas, y Merck confirmó que se habían filtrado los datos cuya publicación estaba prevista para este fin de semana. Las acciones de Moderna se desplomaron hasta un 26% el jueves, un récord intradía, mientras que las de Merck cayeron un 3,9%.
Moderna, Merck Shares Fall After Melanoma Data Was Leaked Original
Shares of and fell after data on the companies’ widely anticipated personalized melanoma vaccine disappointed Wall Street. Shares of Moderna plunged as much as 26% on Thursday, an intraday record, while Merck shares dropped 3.9%. The data were leaked earlier than expected and later confirmed by Merck. The vaccine helped reduce the risk of cancer recurrence by 42% and reduced the risk of distant spread, or metastasis, by 38%.
Moderna, Merck Shares Fall as Leaked Cancer Data Disappoints Original
Photographer: Adam Glanzman/Bloomberg (Bloomberg) -- Moderna Inc.
Europa avanza en la aprobación del fármaco contra el cáncer de páncreas que en EE.UU. cuesta US$475.000 al año
Bloomberg — El medicamento de Revolution Medicines Inc. contra el cáncer de páncreas recibió el respaldo de un comité asesor clave de la Unión Europea, informó la compañía el jueves en un comunicado, lo que acerca este tratamiento, que prolonga la vida de los pacientes, a su llegada al mercado de los 27 países del bloque.
RevMed’s Breakthrough Pancreatic Cancer Drug Gets European Nod
Photographer: Nikos Frazier/Omaha World-Herald/Getty Images (Bloomberg) -- Revolution Medicines Inc.’s pancreatic cancer drug won the backing of a key European Union advisory panel, the company said in a statement Thursday, moving the...
FDA Aims to Overhaul Rare Disease Approvals Under New Leadership Original
The is kicking off a top-to-bottom review of how it approaches rare disease drug development and approvals. The Rare Disease Framework Initiative, being announced Wednesday, aims to develop a system that gives patients more input and companies more clarity in the regulatory process. This comes after a in which several rare disease drugs were unexpectedly rejected or under former FDA commissioner , who in May.
FDA’s New Leadership Aims to Overhaul Rare Disease Approvals
(Bloomberg) -- The US Food and Drug Administration is kicking off a top-to-bottom review of how it approaches rare disease drug development and approvals.
J&J Leans Toward Ortho Spinoff as Medtech Sales Disappoint (1)
reported another quarter of anemic sales in its medical technology division and said it is leaning toward spinning off, rather than selling, its orthopedics business. Medical technology sales rose just 2.5% in the third quarter, missing estimates and trailing more sizable gains in the company’s larger drug business. Overall revenue was roughly in line with expectations, exceeding analyst estimates by the narrowest margin in years.
Johnson & Johnson se inclina por escindir su negocio de ortopedia tras otro trimestre débil
Bloomberg — Johnson & Johnson (JNJ) registró otro trimestre de ventas débiles en su división de tecnología médica y afirmó que se inclina por la escisión, en lugar de la venta, de su negocio de ortopedia. Las ventas de tecnología médica aumentaron apenas un 2,5% en el tercer trimestre, por debajo de las previsiones y restando brillo a las ganancias más significativas del negocio farmacéutico principal de la compañía.
J&J Leans Toward Orthopedic Spinoff as Medtech Sales Disappoint
reported another quarter of anemic sales in its medical technology division and said it is leaning toward a spinoff, rather than a sale, of its orthopedics business. Medical technology sales rose just 2.5% in the third quarter, missing estimates and taking the shine off more sizable gains in the company’s larger drug business. Overall revenue was roughly in line with expectations, exceeding analyst estimates by the narrowest margin in years.
J&J Lifts Earnings Outlook After Quarterly Drug Sales Jump (1)
raised its profit guidance as demand for newer drugs in cancer and autoimmune diseases overshadowed more anemic growth in medical devices, where the company is considering a spin-off of its orthopedics business. J&J now expects adjusted earnings for the full year to be in the range of $11.05 to $11.15 a share, up from a prior view of $10.96 to $11.11. The midpoint of the new range is above .
J&J Lifts Earnings Outlook After Quarterly Drug Sales Jump (1)
Johnson & Johnson raised its profit guidance as demand for newer drugs in cancer and autoimmune diseases overshadowed more anemic growth in medical devices, where the company is considering a spin-off of its orthopedics business.
J&J Leans Toward Ortho Spinoff as Medtech Sales Disappoint
Bloomberg (Bloomberg) -- Johnson & Johnson reported another quarter of anemic sales in its medical technology division and said it is leaning toward spinning off, rather than selling, its orthopedics business.
Johnson & Johnson mulls spinning off orthopedics business as medtech sales disappoint
Johnson & Johnson reported another quarter of anaemic sales in its medical technology division and said it is leaning towards spinning off, rather than selling, its orthopedics business. (Oct 13): Johnson & Johnson reported another quarter of anaemic sales in its medical technology division and said it is leaning towards spinning off, rather than selling, its orthopedics business.
UniQure Sinks After Worse-Than-Expected Huntington’s Results
Bloomberg (Bloomberg) -- UniQure NV slumped in early trading after the benefits of its Huntington’s disease gene therapy were not as good after four years as they were after three years in a small trial — a result that could complicate its bid to...
Científicos cuestionan el alcance del hallazgo genético de Claude anunciado por Anthropic
Bloomberg — El anuncio de Anthropic PBC de que su modelo de IA Claude había descubierto un sistema enzimático similar a una tecnología pionera de edición genética fue recibido con cautela por algunos expertos del sector, quienes sugirieron que la empresa había exagerado su importancia. Ver más: Trump pide frenar acceso de Reino Unido a modelos de OpenAI y Anthropic: EE.UU.
Anthropic’s gene editing discovery isn’t yet a breakthrough, scientists say
Anthropic PBC’s announcement that its Claude AI model discovered an enzyme system that resembled an earlier breakthrough gene editing technology was met with caution by some experts in the field, who suggested the company oversold its significance. In a blog post Wednesday, the AI giant touted a new life sciences group that aims to use Claude to comb through massive DNA datasets to identify proteins for scientists to test in the lab.
Anthropic's Gene Editing Discovery Isn't Yet a Breakthrough, Scientists Say Original
Photographer: Gabby Jones/Bloomberg (Bloomberg) -- Anthropic PBC’s announcement that its Claude AI model discovered an enzyme system that resembled an earlier breakthrough gene editing technology was met with caution by some experts in the field,...
Comité de la FDA respalda prueba de sangre de Grail para detectar múltiples tipos de cáncer
Bloomberg — Un comité de la Administración de Alimentos y Medicamentos de Estados Unidos (FDA, por sus siglas en inglés) dio el miércoles un paso importante hacia la aprobación reglamentaria del primer análisis de sangre capaz de detectar múltiples tipos de cáncer antes de que aparezcan los síntomas. Dicha prueba, desarrollada por Grail Inc. (GRAL), recibió este miércoles respaldo por parte de los miembros del Comité Asesor de Dispositivos Médicos de la FDA.
Grail’s Blood Test to Detect Multiple Cancers Wins FDA Panel Backing
Photographer: Noriko Hayashi/Bloomberg (Bloomberg) -- A US Food and Drug Administration panel took a major step Wednesday toward regulatory approval of the first blood test to detect multiple types of cancer before symptoms emerge.
Live Q&A: Inside the Race for the Next Cancer Breakthrough
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world
NTSB says Amazon cargo jet hit van, car after runway overrun
An Amazon cargo plane crashed at Miami International Airport Sunday afternoon, Sept. 6, 2026, causing a full ground stop that halted all flights. (Al Diaz/Miami Herald/TNS) The Boeing Co. 767 cargo jet that crashed at Miami International Airport overran the runway, and plowed through two vehicles before stopping roughly a quarter-mile past the paved surface, the National Transportation Safety Board said in its first detailed federal account of Sunday's fatal accident.
NTSB says Amazon cargo jet hit van, car after runway overrun
The Boeing Co. 767 cargo jet that crashed at Miami International Airport overran the runway, and plowed through two vehicles before stopping roughly a quarter-mile past the paved surface, the National Transportation Safety Board said in its first detailed federal account of Sunday’s fatal accident.
RevMed's pancreatic cancer pill priced above $475,000 a year
By Robert Langreth and Madison Muller, Bloomberg News Revolution Medicines Inc. won U.S. approval for a breakthrough pill that lengthens the lives of patients with advanced pancreatic cancer, a major advance against one of the hardest-to-treat tumor types. The once-daily drug carries a list price of more than $475,000 a year, making it one of the most expensive cancer treatments in history. The company branded it Rasonque and made it available starting Wednesday.
RevMed’s pancreatic cancer pill priced above $475,000 a year
Revolution Medicines Inc. won U.S. approval for a breakthrough pill that lengthens the lives of patients with advanced pancreatic cancer, a major advance against one of the hardest-to-treat tumor types. The once-daily drug carries a list price of more than $475,000 a year, making it one of the most expensive cancer treatments in history. The company branded it Rasonque and made it available starting Wednesday. kAmxE’D @?6 @7 E96 7:CDE >65:4:?6D E@ 3C@25=J E2C86E #p$[ 2 AC@E6:?
RevMed's pancreatic cancer pill priced above $475,000 a year
Revolution Medicines Inc. won U.S. approval for a breakthrough pill that lengthens the lives of patients with advanced pancreatic cancer, a major advance against one of the hardest-to-treat tumor types. The once-daily drug carries a list price of more than $475,000 a year, making it one of the most expensive cancer treatments in history. The company branded it Rasonque and made it available starting Wednesday.
FDA Clears RevMed’s Breakthrough Pill for Pancreatic Cancer
Revolution Medicines Inc. secured US regulatory approval for its pancreatic cancer drug daraxonrasib, the first medicine to target one of the key molecular causes of the disease. The drug, which will be called Rasonque, is one of the more significant breakthroughs in pancreatic cancer in years.
EE.UU. aprueba fármaco que prolonga la vida de pacientes con cáncer de páncreas
Bloomberg — Revolution Medicines Inc. obtuvo la autorización de las autoridades estadounidenses para un medicamento revolucionario en forma de comprimido que prolonga la vida de los pacientes con cáncer de páncreas avanzado, lo que supone un gran avance en la lucha contra uno de los tipos de tumor más difíciles de tratar.
Breakthrough Pancreatic Cancer Drug Marks New Era for Treatment
Jay Williams, a former movie studio executive, was diagnosed with pancreatic cancer in 2023 when he was just 55. Despite surgery to remove a tumor and multiple rounds of chemotherapy, the disease progressed, eventually spreading to his liver. Toward the start of this year, his doctor bluntly told him he was starting to run out of treatment options. But in early July, Williams qualified for special access to a powerful new drug from .
A Breakthrough Pancreatic Cancer Drug Marks a New Era for Treatment
Photographer: Jason LeCras for Bloomberg Businessweek (Bloomberg Businessweek) -- Jay Williams, a former movie studio executive, was diagnosed with pancreatic cancer in 2023 when he was just 55.
Show More
loading
Actions
Get in touch with Robert
Contact Robert, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack